Lier plans to raise ￥2.088 billion to construct 10000t/a Glufosinate-p and consolidate its C'l chlarnpyridine industry chai

Lier announced on April 27 that, in order to accelerate the realization of development strategy, launch product portfolio suitable for the development of pesticide market, enhance comprehensive competitiveness and improve profitability, it plans to issue shares to specific targets to raise funds not exceeding ￥208,800 million, and the net raised funds plan to invest in the following projects: 

11000t/a pesticide and supporting facilities construction project

In order to expand the scale of existing products, add new varieties, build an internal industrial chain, and consolidate the company's leadership position in the field of C'l chlarnpyridine pesticides, Lier plans to expand its production capacity and build a new 11,000t/a pesticide and supporting facilities. The total investment of the project is ￥540.08 million, and it is planned to use the raised fund of 218.8 million yuan. The main construction projects are 3,000 t/a, 3,000 t/a green grass project, 5,000 t/a enemy grass fast project and related supporting facilities

Fluroxypyr and Triclopyr are mature products produced by the company for many years. Mianyang Base of the company has Fluroxypyr production lines of 1,500 t/a and Triclopyr production lines of 2,200 t/a, and Fluroxypyr and Triclopyr have good market space. Therefore, the company plans to add new production lines in Guang 'an base to improve production capacity

TCPA sodium salt chemical intermediates and supporting engineering projects

In order to seize the market opportunity, Lier is in urgent need of meeting the market demand for its main products such as Clopyralid, Picloram and Aaminopyralid. However, the production capacity of TCPA sodium salt, the key intermediate, is limited. Therefore, the company plans to start the construction of TCPA sodium salt chemical intermediate and its supporting engineering project. The total investment of this project is 60,500,000 yuan, and it is planned to use the raised fund of 30,800,000 yuan.

After years of development, Lier's main C'l chlarnpyridine products such as Clopyralid, Picloram and Aaminopyralid have become one of the company's important and stable sources of revenue and profit. The Hebi base of the company has 2-Methylpyridine production line, which is the key raw material for the upstream production of TCPA sodium salt. The company has formed a complete industrial chain of 2-Methylpyridine to 2-Cyanopyridine, and then to pesticide agents Clopyralid, Picloram and Aaminopyralid, which effectively reduces the cost and greatly improves the ability of supply security. So as to improve the market competitiveness and profitability of Clopyralid, Picloram.

10000t/a Glufosinate-p and public auxiliary engineering project

As the leading enterprise in the production of Glufosinate technical, Lier Chemical has mastered the production technology of Glufosinate-p biochemical method after years of research and development, and has the technical conditions for implementation. In order to meet the needs of customers as soon as possible, seize the market and take the lead, the company plans to build a production line of 10,000 t/a of biochemical method based on the 20,000 t/a of enzymatic method of Glufosinate-p. The total investment of this project is 10666 million yuan, and it is planned to use the raised fund of 9366 million yuan.

As the world's leading enterprise of Glufosinate, Lier has a congenital competitive advantage in the market of Glufosinate-p, has obtained the technical certificate of Glufosinate-p., and has carried out the global strategic layout. The core process in the production of r Glufosinate-p. is the first in the world and China. The company has continuously innovated on the process, formed a number of high-value patents, and actively promoted the global layout of patents, and the technology is at the global leading level. Combined with the advantages of high quality and low cost brought by the advanced technology route adopted in this project, the company can quickly gain the leading edge when it has the first-mover advantage. The company will continue to maintain the leading position in Glufosinate and Glufosinate-p, seize the strategic opportunities, and ensure the sustainable and stable development of the company. The industrialization production technology of this project has been mature, and the intermediates involved are independent and supporting. Therefore, this technical route is completely independent and feasible, and can be scaled up.

Supplementary working capital items

In consideration of the industry status quo, development strategy, financial condition, market financing environment and other internal and external conditions, Lier Chemical intends to use 626,600 yuan of the funds raised by issuing shares to specific targets to supplement the working capital, so as to meet the needs of the company's continuous business development for working capital and promote the healthy development of the company's main business. Achieve strategic development goals.